Literature DB >> 14668695

Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure.

Peter A McCullough1, Joseph Kuncheria, Vandana S Mathur.   

Abstract

Chronic kidney disease (CKD) and congestive heart failure (CHF) are epidemiologically and pathophysiologically linked. A recent study in patients with severe CHF demonstrated that renal plasma flow was inversely correlated with pulmonary capillary wedge pressure, right atrial pressure, pulmonary pressure, and right ventricular ejection fraction. This article reviews the utility of B-type natriuretic peptide (BNP) levels in assessing cardiac function and volume status in patients with CKD and examines the safety and efficacy of BNP therapy in patients with renal insufficiency and decompensated heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668695

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  3 in total

Review 1.  The emerging role of natriuretic peptides in the diagnosis and treatment of decompensated heart failure.

Authors:  Michael J Gallagher; Peter A McCullough
Journal:  Curr Heart Fail Rep       Date:  2004-09

2.  Cardiac magnetic resonance defines mechanisms of sex-based differences in outcomes following cardiac resynchronization therapy.

Authors:  Derek J Bivona; Srikar Tallavajhala; Mohamad Abdi; Pim J A Oomen; Xu Gao; Rohit Malhotra; Andrew Darby; Oliver J Monfredi; J Michael Mangrum; Pamela Mason; Sula Mazimba; Michael Salerno; Christopher M Kramer; Frederick H Epstein; Jeffrey W Holmes; Kenneth C Bilchick
Journal:  Front Cardiovasc Med       Date:  2022-09-15

3.  B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.

Authors:  Lena Jafri; Waqar Kashif; Javed Tai; Imran Siddiqui; Iqbal Azam; Hira Shahzad; Farooq Ghani
Journal:  BMC Nephrol       Date:  2013-05-31       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.